Search
Telapristone acetate
go.drugbank.com/drugs/DB05253InvestigationalTelapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Biomed 101
go.drugbank.com/drugs/DB05851InvestigationalBiomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid.
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigationalautoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.
Peptide YY (3-36)
go.drugbank.com/drugs/DB05004InvestigationalIt reduces appetite and increases satiety in obese patients.
ONT-093
go.drugbank.com/drugs/DB14069ExperimentalIn pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).
Siltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.
Tubocurarine
go.drugbank.com/drugs/DB01199ApprovedWithdrawn[A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen. … [A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048]
Synonyms: d-tubocurarineNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalDesmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase
XL844
go.drugbank.com/drugs/DB05149InvestigationalXL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.
Corticorelin
go.drugbank.com/drugs/DB05394InvestigationalCorticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory.